Ameliorating Effects of Silymarin-Loaded PLGA on Acetaminophen-Induced Nephrotoxicity in Mice

Samaneh Karimi¹,2,*, Maryam Mombeini³, Mohammadreza Abbaspour⁴, Fereshtesadat Fakhredini⁵ and Luqman Khan⁶

¹Department of Anatomical Sciences, School of Medicine, Abadan University of Medical Sciences, Abadan, Iran
²Student Research Committee, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
³Cell and Molecular Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
⁴Targeted Drug Delivery Research Center, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
⁵Department of Anatomical Sciences, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
⁶Faculty of Medicine, University of Rijeka, Rijeka, Croatia

*Corresponding author: Department of Anatomical Sciences, School of Medicine, Abadan University of Medical Sciences, Abadan, Iran. Email: samaneh_k_500@yahoo.com

Abstract

Background: Silymarin (SM) has beneficial effects against numerous different types of toxicants. However, the low bioavailability of SM has limited its therapeutic effects.

Objectives: This study investigated the toxic effect of nanostructured SM (NSM) in poly(lactic-co-glycolic acid) (PLGA) nanoparticles on nephrotoxicity induced by acetaminophen (APAP) in mice.

Methods: The encapsulation of SM in PLGA was performed by the solvent evaporation method. A total of 48 NMRI mice were used in this experimental study. The mice were pretreated with SM or NSM (5 mg/kg) for 7 days, and APAP (300 mg/kg) was administrated on the 6th day. The serum levels of blood urea nitrogen, creatinine, and uric acid were measured. Histological assessment and messenger ribonucleic acid expression of BAX and BCL-2 genes were also carried out.

Results: The APAP destroyed the structure of the renal tissue and significantly reduced renal weight and glomerulus diameters (P < 0.01). The APAP also caused a significant increase in the serum levels of biochemical markers (P < 0.001) and expression of the BAX/BCL-2 ratio in the renal tissue (P < 0.001). The NSM could improve the renal structure and significantly increase renal weight and glomerulus in the APAP-intoxicated mice. The NSM significantly reduced the level of the biochemical tests and the BAX/BCL-2 ratio in the APAP-treated group (P < 0.01).

Conclusions: The obtained data indicate that PLGA effectively enhances the nephroprotective effects of SM on nephrotoxicity induced by APAP.

Keywords: Acetaminophen, Silymarin, PLGA, Apoptosis

1. Background

Acetaminophen (APAP) is a commonly used analgesic and antipyretic drug. If APAP is used in high doses, liver necrosis and nephrotoxicity can occur in laboratory animals and humans (1). The APAP induces an animal model of nephrotoxicity to evaluate the efficacy of new therapeutic agents.

Silymarin (SM) is extracted from the Silybum marianum L. Gaertn (milk thistle) seeds. It is a flavonoid with various biological impacts, such as cardioprotective, hepatoprotective, and anticancer (2-5). The SM protects the kidney against toxicants, such as cisplatin, vancomycin, and methotrexate (6-8). However, low aqueous solubility, poor permeability, and extensive metabolism of SM limit its therapeutic usage.

Several protocols, such as incorporating microspheres, liposomes, nanocarriers, and poly(lactic-co-glycolic acid) (PLGA) nanoparticles, improved the bioavailability and solubility of SM. The PLGA is a nontoxic and biodegradable polymer appropriate for tissue engineering, gene therapy, and drug delivery (9). The PLGA encapsulation effectively enhances the hepatoprotective effects of SM (10).

The APAP causes damage to the mitochondrial membrane and releases cytochrome c in response to oxidative stress, causing apoptosis in target cells. The BCL-2 family genes located in the inner mitochondrial membrane regulate the release of cytochrome c (11). Two groups of pro-apoptotic and anti-apoptotic genes exist in the BCL-2 family. The release of cytochrome c from the mitochon-
dria into the cytosol is brought about by the pro-apoptotic proteins, such as Bax. The anti-apoptotic genes, such as BCL-2 and BCL-XL, cause the prevention of the release of cytochrome c into the cytosol and inhibition of apoptosis. Therefore, the ratio of BAX to BCL-2 was used to identify the inducing apoptosis in various cells (12).

2. Objectives

The present study evaluated the effect of nanostructured SM (NSM) against APAP-induced nephrotoxicity and apoptosis.

3. Methods

3.1. Preparation of Nanostructured Silymarin

Loading SM in PLGA was performed by solvent evaporation protocol. In brief, 4% PLGA (w/v) was provided in 1:4 acetone. Ethyl acetate solution had 0.58% (w/v) SM added to 4 mL of polyvinyl alcohol (PVA) (1% w/v) diluted in water. The prepared nanoemulsion was mixed with 6 mL of 0.5% PVA solution, and the dissolved organic solvents were deleted by a rotavapor. The supernatants were centrifuged at 12,000 rpm for 20 minutes, and the produced pellet was dispersed in deionized water and lyophilized.

3.2. Characterization of Nanostructured Silymarin

The mean particle size and size distribution of NSM were assessed using a dynamic light scattering device. The charge of the SM-loaded PLGA (Zeta potential) was determined by a Zeta-sizer system (Malvern, UK). The morphology of NSM was examined by transmission electron microscopy.

The entrapment efficiency (EE) was calculated using the following formula:

$$\% \text{EE} = \left( \frac{\text{Total SM amount in the supernatant}}{\text{Total SM}} \right) \times 100$$

For the determination of SM release from PLGA, NSM was enclosed in a dialysis bag, placed in 100 mL phosphate-buffered saline, and analyzed spectrophotometrically at 287 nm. The percentage of SM release was calculated by the following formula:

$$\% \text{SM release} = \left( \frac{\text{Amount of SM release}}{\text{Amount of SM in PLGA}} \right) \times 100$$

3.2.1. Animals

A total of 48 male NMRI mice (weight range: 20 - 25 g; age range: 6 - 8 weeks) were used in this experimental study. The mice were provided by the Experimental Research Center of Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. The mice were maintained on a 12-hour-dark and 12-hour-light cycle, with a relative humidity of 50 ± 5% and 22 ± 3°C. The mice had free access to commercial food (pellet) and water. The current study was approved by the Ethics Committee of Ahvaz Jundishapur University of Medical Sciences (IR.AJUMS.REC.1393.151).

3.2.2. Experimental Design

The mice were randomly divided into six following groups:

(1) Control group: Received only normal saline.
(2) SM group: Received 5 mg/kg SM for 7 days by intragastric gavage.
(3) NSM group: Received 5 mg/kg NSM for 7 days by intragastric gavage.
(4) APAP-intoxicated group: Normal saline was given for 7 days, and 300 mg/kg of APAP was injected on the 6th day.
(5) SM + APAP group: Received 5 mg/kg of SM for 7 days, and APAP was injected on the 6th day.
(6) NSM + APAP group: Received 5 mg/kg of NSM for 7 days, and APAP was injected on the 6th day.

One day after APAP administration, the animals were anesthetized with ketamine/xylazine, and their blood samples were collected. The mice were then euthanized, and their kidneys were removed in formalin for histological assessments or maintained at -80°C to determine gene expression.

3.3. Biochemical Tests

The blood samples were collected in a heparinized tube and centrifuged. The serums were isolated and stored at -70°C for biochemical tests. The serum concentrations of uric acid, creatinine (Cr), and blood urea nitrogen (BUN) were determined spectrophotometrically using available kits (Sigma-Aldrich, USA).

3.4. Histology Changes

In this study, 6 hematoxylin-eosin-stained sections per mouse were evaluated for histological criteria, including nuclear pyknosis, infiltration of inflammatory cells, brush border loss, and congestion of red blood cells (RBCs). The histological criteria were graded into four categories, namely normal (-), weak (+), moderate (++), or intense (+++). The glomerular diameter was determined by Motic Images Plus 2.0, an image analysis software.
3.5. Real-time Polymerase Chain Reaction

An RNeasy kit was used to isolate the ribonucleic acid of the kidneys, and a complementary deoxyribonucleic acid (cDNA) kit was utilized to convert it to cDNA. The cDNA amplified in polymerase chain reaction (PCR) reaction contained primers (Appendix 1) and SYBR Green. For PCR amplification, a 45-cycle program, including 95°C for 10 seconds, 95°C for 15 seconds, 60°C for 20 seconds, and 60°C for 20 seconds, was used. In this study, the GAPDH gene was used to normalize target genes. The relative expression of genes was investigated using the 2^-∆∆CT method.

3.6. Data Analysis

The data are presented as mean and standard deviation. A one-way analysis of variance followed by a Tukey’s test was used to calculate differences between group means. When the P-value was less than 0.05, the results were deemed statistically significant.

4. Results

4.1. Characterization of Nanostructured Silymarin

The average particle size of SM-loaded PLGA was about 126 nm. In scanning electron microscopy evaluation, SM had a uniform, discrete, and spherical shape. The EE of NSM was 89.18%. The in vitro drug release profile exhibited an initial burst release until 2 hours and then showed a slow release of SM. The slow release of NSM was continued for 24 hours (Figure 1). Zeta potential results indicated that NSM had good stability for encapsulating SM (Table 1).

4.2. Organ Weight

No significant difference was observed in body weight between the control and experimental groups. Organ weight in SM or NSM-treated mice was similar to the controls. Renal weights in APAP-intoxicated mice had significantly reduced, compared to the controls (P < 0.01). The pretreatment of SM slightly increased the renal weights, compared to the APAP-intoxicated animals (P < 0.05). In NSM + APAP-treated mice, the renal weights were significantly higher than in the APAP and SM + APAP groups (Figure 2).

4.3. Biochemical Tests

In SM and NSM groups, the serum levels of uric acid, Cr, and BUN did not significantly change compared to the control animals. The serum concentration of the biomarkers significantly elevated in the APAP group (P < 0.001). The pretreatment of SM could not significantly change the biomarker levels compared to the APAP-intoxicated animals. In the NSM + APAP group, the serum level of biomarkers was significantly reduced, compared to the APAP + SM and APAP-treated animals (Figure 3).

4.4. Histology

All kidney sections had a normal appearance in the control, SM, and NSM groups. The administration of APAP considerably increased the infiltration of inflammatory cells, congestion of RBCs, and proximal cell damage. Nevertheless, the glomerular diameter was significantly reduced (P < 0.01). The administration of SM + APAP slightly changed the proximal tubule damages (P < 0.05), infiltration of inflammatory cells, congestion of RBCs, and glomerular diameter (P < 0.01), compared to the APAP-intoxicated animals. In the NSM + APAP group, histological criteria significantly reduced, compared to the APAP and SM + APAP groups. The NSM could also increase the glomerular diameter in the APAP-intoxicated mice (Figure 4).

4.5. Real-time Polymerase Chain Reaction

In the APAP group, the expression of the BAX gene in the renal tissue was significantly increased, compared to the control group (P < 0.01). Nonetheless, APAP significantly reduced the expression of the BCL-2 gene. In the SM + APAP group, the expression of the BAX gene in the renal tissue was significantly decreased, compared to the APAP group (P < 0.05). However, the expression of BCL-2 was significantly increased (Figure 5).

In the NSM + APAP group, the expression of the BAX gene in the renal tissue was significantly decreased, compared to the APAP and SM + APAP groups (P < 0.01). Nevertheless, the expression of BCL-2 was significantly increased, compared to the APAP and SM + APAP groups (Figure 5).

The ratio of BAX/BCL-2 in the APAP-intoxicated rats was considerably increased, compared to the controls (P < 0.001). In the SM + APAP group, the ratio of BAX/BCL-2 in the renal tissue was significantly increased, compared to the APAP group (P < 0.01). In the NSM + APAP group, the BAX/BCL-2 ratio in the renal tissue was significantly reduced, compared to the APAP and SM + APAP groups (Figure 5).

5. Discussion

In the present study, SM was successfully encapsulated in PLGA, and this encapsulation could effectively enhance SM’s nephroprotective impacts against APAP-induced renal toxicity in mice. The increased nephroprotective impacts of NSM might be due to the increased bioavailability of SM by PLGA. In a previous study, a liposomal formulation increased the oral bioavailability of SM (13). The SM nanoemulsion attenuates tetrachloride-caused liver damage (14). The NSM, due to its small size, might better penetrate the renal tissues compared to the free SM. Moreover, NSM
Table 1. Characteristic of Silymarin Loaded in Poly(lactic-co-glycolic Acid) 

| Nanoparticles | Particle size (nm) | PDI     | ZP          | EE (%)     |
|---------------|--------------------|---------|-------------|------------|
| SM-PLGA       | 82.3 ± 5.8         | 0.14 ± 0.05 | -28.4      | 89.18 ± 6.4 |
| Blank-PLGA    | 80.13 ± 6.7        | 0.12 ± 0.06 | -27.3      | -          |

Abbreviations: ZP, Zeta potential; PDI, polydispersity index; EE, encapsulation efficacy; SM, silymarin; PLGA, poly(lactic-co-glycolic acid)  

Values are expressed as mean ± standard deviation.

Figure 1. Characterization of silymarin (SM) loaded in poly(lactic-co-glycolic acid) (PLGA); A, Zeta potential; B, transmission electron microscopy micrograph of SM-PLGA; C, percentage of the drug release during 24 hours.

might escape from macrophages, and its clearance might be prolonged and therefore improve the therapeutic index of SM.

In the APAP-intoxicated mice, an increase in the serum levels of BUN, Cr, and uric acid occurred. The serum levels of these markers are sensitive to any kidney disorder. When the kidney is damaged, these biomarkers, which are inside the proximal cells of nephrons, release into the bloodstream. Therefore, the elevated concentration of these biomarkers indicates proximal cell destruction (15). In this study, NSM effectively ameliorated the serum levels of BUN, Cr, and uric acid. Pretreatment with methanolic extract of SM declined Cr clearance and proteinuria and attenuated proximal tubule injury of rats (16).

In the APAP-intoxicated mice, the increased levels of biomarkers were accompanied by increasing histological criteria. As shown in the results, SM significantly attenuated histological changes induced by APAP. Kumar et al. showed that NSM had more anti-inflammatory action in comparison to the free SM in liver tissue (13). The anti-inflammatory effects of SM have also been reported by Gupta et al. (17). Bektur et al. showed that SM had protec-
Figure 2. Renal weight in different groups; control, silymarin (SM), nanostructured silymarin (NSM), acetaminophen (APAP), SM + APAP, NSM + APAP. Mean ± standard deviation; (n = 8) * P < 0.05 and # P < 0.05; * and # indicating comparison to the control and acetaminophen groups.

Figure 3. Biochemical tests in various groups (mean ± standard deviation; n = 8) control, silymarin (SM), nanostructured silymarin (NSM), acetaminophen (APAP), SM + APAP, NSM + APAP; * P < 0.05, ** P < 0.01, # P < 0.05, and ## P < 0.01; * and # indicating comparison to the control and acetaminophen groups.
As mentioned in the results, kidney weights decreased in the APAP group. It might have been the result of the proximal tubule and glomerular damage. In the APAP-intoxicated mice, the decline in renal weight was accompanied by an increase in the $\text{BAX}/\text{BCL-2}$ ratio. This finding indicates that apoptosis is involved in APAP-induced nephrotoxicity, which is in line with the results of previous studies (1, 8). As mentioned in the results, NSM could significantly reduce the $\text{BAX}/\text{BCL-2}$ ratio indicating the anti-apoptotic action of NSM. In line with the results of the current study, the anti-apoptotic impacts of SM against cisplatin and aminoglycoside are reported (19). The reduced $\text{BAX}/\text{BCL-2}$ ratio in the NSM + APAP group indicated the anti-apoptotic impact of NSM on the renal tissue.

5.1. Conclusions
In this study, SM-PLGA nanoparticles (NSM) were developed to improve the renoprotective effect of SM. The NSM could effectively increase renal weight and reduce apoptosis by decreasing the $\text{BAX}/\text{BCL-2}$ ratio in the renal tissue of mice. Further studies are required to prove the anti-apoptotic impacts of NSM on nephrotoxic renal tissues.

Supplementary Material
Supplementary material(s) is available here [To read supplementary materials, please refer to the journal website and open PDF/HTML].

Footnotes
Authors’ Contribution: S. K., M. R. A., and M. M.: Conception and design of the study; S. K. and M. M.: Acquisition and analysis of the data; S. K. and F. F.: Writing, reviewing, and editing; S. K.: Drafting and revising the article.
Figure 5. Micrographs of hematoxylin-eosin-stained slides of various groups; control, silymarin (SM), nanostructured silymarin (NSM), acetaminophen (APAP), SM + APAP, NSM + APAP; I, infiltration of inflammatory cells; C, congestion of red blood cells; P, damaged proximal tubules; magnifications: X100

Conflict of Interests: The authors declare no conflict of interests.

Data Reproducibility: The data presented in this study are uploaded during submission as a supplementary file and are openly

Ethical Approval: The current study was approved by the Ethics Committee of Ahvaz Jundishapur University of Medical Sciences (IR.AJUMS.REC.1393.151).

Funding/Support: The present study was funded by Ahvaz Jundishapur University of Medical Sciences (93 s53).

References

1. Park WY. Controversies in acetaminophen nephrotoxicity. *Kidney Res Clin Pract*. 2020;39(4):4–6. doi: 10.23876/krcp.20.027. [PubMed: 32787973]. [PubMed Central: PMC7805628].

2. Razavi BM, Karimi G. Protective effect of silymarin against chemical-induced cardiotoxicity. *Iran J Basic Med Sci*. 2016;19(5):916–23. [PubMed: 27803777]. [PubMed Central: PMC5080420].

3. Gillessen A, Schmidt HH. Silymarin as Supportive Treatment in Liver Diseases: A Narrative Review. *Adv Ther*. 2020;37(4):1279–301. doi: 10.1007/s12325-020-01251-y. [PubMed: 32065376]. [PubMed Central: PMC7140758].

4. Koltai T, Fliegel L. Role of Silymarin in Cancer Treatment: Facts, Hypotheses, and Questions. *J Evid Based Integr Med*. 2022;27. doi: 10.1177/2515690X211068826. [PubMed: 35018864]. [PubMed Central: PMC8148427].

5. Snima KS, Arunkumar P, Jayakumar R, Lakshmanan VK. Silymarin encapsulated poly(D,L-lactic-co-glycolic acid) nanoparticles: a prospective candidate for prostate cancer therapy. *J Biomed Nanotechnol*. 2014;10(4):5559–70. doi: 10.1166/jbn.2014.1715. [PubMed: 24734508].

6. Guzel S, Sahinogullari ZU, Canancakantan N, Antmen SE, Kibar D, Coskun Vilmaz B. Potential renoprotective effects of silymarin against vancomycin-induced nephrotoxicity in rats. *Drug Chem Toxicol*. 2020;43(6):530–6. doi: 10.1080/04480545.2019.1584208. [PubMed: 32862206].

7. Shahbazi F, Sadighi S, Dashhti-Khavidaki S, Shahi F, Mitrania M, Abdullahi A, et al. Effect of Silymarin Administration on Cisplatin Nephrotoxicity: Report from A Pilot, Randomized, Double-Blinded, Placebo-Controlled Clinical Trial. *Phytother Res*. 2015;29(7):1046–53. doi: 10.1002/ptr.5345. [PubMed: 25875166].

8. Dabak DO, Kocaman N. Effects of silymarin on methotrexate-induced nephrotoxicity in rats. *Ren Fail*. 2015;37(4):734–9. doi: 10.3109/0886022X.2015.1029984. [PubMed: 25707599].

9. Di Costanzo A, Angelico R. Formulation Strategies for Enhancing the Bioavailability of Silymarin: The State of the Art. *Molecules*. 2019;24(10). doi: 10.3390/molecules24102155. [PubMed: 31186187]. [PubMed Central: PMC6600503].

10. Durymanov M, Pempyakova A, Reineke J. Pre-treatment With PLGA/Silibinin Nanoparticles Mitigates Dacarbazine-Induced Hepatotoxicity. *Front Bioeng Biotechnol*. 2020;8:495. doi: 10.3389/fbioe.2020.00495. [PubMed: 32670224]. [PubMed Central: PMC732747].

11. Kumar A, Kakkar P. Lupeol prevents acetaminophen-induced in vivo hepatotoxicity by altering the Bax/Bcl-2 and oxidative stress-mediated mitochondrial signaling cascade. *Life Sci*. 2012;90(15-16):560–70. doi: 10.1016/j.lfs.2012.01.012. [PubMed: 22364599].

12. Suraweera CD, Banjara S, Hinds MG, Kvansakul M. Metazoans and Intrinsic Apoptosis: An Evolutionary Analysis of the Bcl-2 Family. *Int J Mol Sci*. 2022;23(7). doi: 10.3390/ijms23073691. [PubMed: 35409052]. [PubMed Central: PMC8998226].

13. Kumar N, Rai A, Reddy ND, Raj PV, Jain P, Deshpande P, et al. Silymarin liposomes improves oral bioavailability of silybin besides targeting hepatocytes, and immune cells. *Pharmacoepidemiol Rep*. 2014;5(5):278–88. doi: 10.1016/j.pheare.2014.04.007. [PubMed: 25149982].

14. Parveen R, Babooa S, Ali J, Ahuja A, Vasudev SS, Ahmad S. Effects of silymarin nanoemulsion against carbon tetrachloride-induced hepatic damage. *Arch Pharm Res*. 2011;34(5):767–74. doi: 10.1007/s12272-011-0510-8. [PubMed: 21656162].
15. Mazer M, Perrone J. Acetaminophen-induced nephrotoxicity: pathophysiology, clinical manifestations, and management. *J Med Toxicol*. 2008;4(1):2–6. doi: 10.1007/BF03160941. [PubMed: 18338302]. [PubMed Central: PMC3550099].

16. Karimi G, Fallah Huseini H, Ramezani M, Tahoonian Z. Protective effect of silybum marianum (L.) gaertn. seeds extract and silymarin against cisplatin-induced acute nephrotoxicity in rats. *J Med Plants*. 2005;4(13):42–5. Persian.

17. Gupta OP, Sing S, Bani S, Sharma N, Malhotra S, Gupta BD, et al. Anti-inflammatory and anti-arthritic activities of silymarin acting through inhibition of 5-lipoxygenase. *Phytomedicine*. 2000;7(1):21–4. doi: 10.1016/S0944-7113(00)80017-3. [PubMed: 10782486].

18. Bektur NE, Sahin E, Baycu C, Unver G. Protective effects of silymarin against acetaminophen-induced hepatotoxicity and nephrotoxicity in mice. *Toxicol Ind Health*. 2016;32(4):589–600. doi: 10.1177/0748233713502841. [PubMed: 24993058].

19. Dashti-Khavidaki S, Shahbazi F, Khalili H, Lessan-Peleshk M. Potential renoprotective effects of silymarin against nephrotoxic drugs: a review of literature. *J Pharm Pharm Sci*. 2012;15(1):112–23. doi: 10.18433/j3f88s. [PubMed: 22365093].